Passage Bio director Liam Ratcliffe resigns over disagreement on business plans

Passage BIO, Inc.

Liam Ratcliffe, MD, Ph.D., resigned from the Board and its Nominating and Governance Committee, effective March 7, 2022.
Resignation cited a disagreement with the company regarding its business plans and operations.
No replacement announced; Board size reduced.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Liam Ratcliffe

Director

PASG · Passage BIO, Inc.

Effective: 2022-03-07
Filed: March 11, 2022, 6:59 PM ET

On March 7, 2022, Liam Ratcliffe, MD, Ph.D., notified Passage Bio, Inc. (the “Company”) of his decision to resign from the Company’s Board of Directors (the “Board”), including from the Nominating and Governance Committee of the Board, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Liam Ratcliffe resigned as Director at Passage BIO, Inc..

Action: resigned
Role: Director

Exact text from the filing

On March 7, 2022, Liam Ratcliffe, MD, Ph.D., notified Passage Bio, Inc. (the “Company”) of his decision to resign from the Company’s Board of Directors (the “Board”), including from the Nominating and Governance Committee of the Board, effective immediately.

View on SEC.gov

Passage BIO, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-032947

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.